Assessment of Lumacaftor/Ivacaftor therapy on physical activity and exercise tolerance in adults with cystic fibrosis
A. Porcella (Rome, Italy), A. Gramegna (Milan, Italy), M. Di Paolo (Rome, Italy), M. Vicenzi (Milan, Italy), I. Rota (Milan, Italy), C. Biglia (Orbassano, Italy), B. Messore (Orbassano, Italy), E. Leggieri (Rome, Italy), F. Blasi (Milan, Italy), P. Palange (Rome, Italy), D. Savi (Rome, Italy)
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Porcella (Rome, Italy), A. Gramegna (Milan, Italy), M. Di Paolo (Rome, Italy), M. Vicenzi (Milan, Italy), I. Rota (Milan, Italy), C. Biglia (Orbassano, Italy), B. Messore (Orbassano, Italy), E. Leggieri (Rome, Italy), F. Blasi (Milan, Italy), P. Palange (Rome, Italy), D. Savi (Rome, Italy). Assessment of Lumacaftor/Ivacaftor therapy on physical activity and exercise tolerance in adults with cystic fibrosis. 364
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: